This proposal is for a 5 year renewal (years 16-20) of the Alzheimer's Disease Cooperative Study (ADCS). This consortium of 34 members'sites and 46-56 participating sites is proposing both continued instrument development as well as new clinical drug studies. Instrument development will focus on innovative methods of home based assessments for a broad cohort of normal elderly(over age 75) who may have significant co-morbidities in a simulated primary prevention trial employing mail-in questionnaires, automated telephone technology and computerized data collection to assess cognitive, functional, affective, global, quality of life, and resource use measures in the home environment. The ADCS has assembled its most exciting portfolio of clinical drug trials by seeking new and innovative compounds form the biotechnology sector, individual investigator laboratories as well as from its own members. We are proposing 3 phase 3 efficacy trials of agents designed to slow progression of AD: (1) TTP488, a small novel molecule that binds to and inhibits the receptor for advanced glycation end products (RAGE) which blocks deposition of A?, (2) NAP, a novel eight amino acid peptide derived from the sequence of activity dependent neuroprotective protein(ADNP), the most potent neuroprotectant molecule currently known and (3) docosahexaenoic acid (DHA), an omega-3 fatty acid with anti-amyloid, anti-oxidant, and neuroprotectant effects. Two biomarker trials are proposed to determine if molecules of interest can produce a measurable biological signal for consideration for future efficacy trials: (1) Li, a molecule that blocks phosphorylation of tau protein and (2) resveratrol, a polyphenol derived from plants and red wine that retards the age-dependent deposition and accumulation of CNS A? and amyloid plaques. Finally, we will test the ability of passive immunization using Mg which contains natural anti-amyloid antibodies and has been demonstrated to improve cognition in early clinical trials in AD. Our existing minority recruitment core is being expanded into a general recruitment core focused on maximizing the recruitment of minorities and other subjects into our clinical trials.

National Institute of Health (NIH)
National Institute on Aging (NIA)
Research Project--Cooperative Agreements (U01)
Project #
Application #
Study Section
Special Emphasis Panel (ZAG1-ZIJ-7 (M2))
Program Officer
Ryan, Laurie M
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of California San Diego
Schools of Medicine
La Jolla
United States
Zip Code
Katsumata, Yuriko; Nelson, Peter T; Ellingson, Sally R et al. (2017) Gene-based association study of genes linked to hippocampal sclerosis of aging neuropathology: GRN, TMEM106B, ABCC9, and KCNMB2. Neurobiol Aging 53:193.e17-193.e25
Jacobs, Diane M; Ard, M Colin; Salmon, David P et al. (2017) Potential implications of practice effects in Alzheimer's disease prevention trials. Alzheimers Dement (N Y) 3:531-535
Sims, Rebecca (see original citation for additional authors) (2017) Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease. Nat Genet 49:1373-1384
Spencer, Brian; Valera, Elvira; Rockenstein, Edward et al. (2017) Anti-?-synuclein immunotherapy reduces ?-synuclein propagation in the axon and degeneration in a combined viral vector and transgenic model of synucleinopathy. Acta Neuropathol Commun 5:7
Moussa, Charbel; Hebron, Michaeline; Huang, Xu et al. (2017) Resveratrol regulates neuro-inflammation and induces adaptive immunity in Alzheimer's disease. J Neuroinflammation 14:1
Jun, Gyungah R; Chung, Jaeyoon; Mez, Jesse et al. (2017) Transethnic genome-wide scan identifies novel Alzheimer's disease loci. Alzheimers Dement 13:727-738
Sokolow, Sophie; Li, Xiaohui; Chen, Lucia et al. (2017) Deleterious Effect of Butyrylcholinesterase K-Variant in Donepezil Treatment of Mild Cognitive Impairment. J Alzheimers Dis 56:229-237
Insel, Philip S; Mattsson, Niklas; Mackin, R Scott et al. (2016) Accelerating rates of cognitive decline and imaging markers associated with ?-amyloid pathology. Neurology 86:1887-96
Ott, B R; Pelosi, M A; Tremont, G et al. (2016) A Survey of Knowledge and Views Concerning Genetic and Amyloid PET Status Disclosure. Alzheimers Dement (N Y) 2:23-29
Zlatar, Zvinka Z; Bischoff-Grethe, Amanda; Hays, Chelsea C et al. (2016) Higher Brain Perfusion May Not Support Memory Functions in Cognitively Normal Carriers of the ApoE ?4 Allele Compared to Non-Carriers. Front Aging Neurosci 8:151

Showing the most recent 10 out of 288 publications